GlassScriptPhysician profile
Ryan K Miyamoto
NPI 1245415454
$2,685.04
in general payments reported to CMS, 2019-2025
31 companies · $569 in 2025
The $569 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $55.16 · 2021: $11.12 · 2022: $430 · 2023: $677 · 2024: $404 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.59 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $416.51 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $391.67 | 2019-2025 | Erleada, Akeega |
| Endo Pharmaceuticals INC. | $209.06 | 2019-2023 | Aveed, Xiaflex, Edex |
| Medtronic, INC. | $204.42 | 2022-2024 | Interstim |
| Boston Scientific Corporation | $137.06 | 2023-2025 | Advantage System, Lithovue |
| Abbvie INC. | $126.84 | 2022-2025 | |
| Olympus America INC. | $125.79 | 2019-2024 | Bovie, Itind System, Cysto-Nephro Videoscope |
| Pfizer INC. | $121.37 | 2019-2025 | |
| Astellas Pharma US INC | $116.56 | 2019-2022 | |
| Intuitive Surgical, INC. | $87.51 | 2025 | |
| Progenics Pharmaceuticals, INC. | $82.04 | 2022-2025 | |
| Allergan, INC. | $75.25 | 2019-2021 | |
| Coloplast Corp | $70.48 | 2019-2023 | Speedicath |
| Urogen Pharma, INC. | $65.31 | 2022-2025 | |
| Rochester Medical Corporation | $43.17 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $41.02 | 2019 | |
| Urovant Sciences INC | $35.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Procept Biorobotics Corporation | $33.69 | 2025 | |
| Ferring Pharmaceuticals INC. | $32.51 | 2019 | |
| Abc Home Medical Supply, INC. | $31.48 | 2022-2023 | |
| Medtronic USA, INC. | $30.33 | 2019 | |
| Neotract INC. | $30.19 | 2019 | |
| Ambu INC. | $22.22 | 2025 | |
| 180 Medical, INC. | $20.33 | 2023 | Gentlecath |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.11 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.88 | 2025 | |
| Tolmar, INC. | $16.26 | 2023 | |
| Endo USA, INC. | $15.54 | 2024 | Xiaflex |
| C. R. Bard, INC. & Subsidiaries | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Miyamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.